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tic fibrosis (CF) is a lethal recessive genetic disease caused primarily
by the F508del mutation in the CF transmembrane conductance
regulator (CFTR). The potentiator VX-770 was the first CFTR mod-
ulator approved by the FDA for treatment of CF patients with the
gating mutation G551D. Orkambi is a drug containing VX-770 and
corrector VX809 and is approved for treatment of CF patients ho-
mozygous for F508del, which has folding and gating defects. At least
30% of CF patients are heterozygous for the F508del mutation with
the other allele encoding for one of many different rare CFTR
mutations. Treatment of heterozygous F508del patients with VX-809
and VX-770 has had limited success, so it is important to identify
heterozygous patients that respond to CFTR modulator therapy.
R117H is a more prevalent rare mutation found in over 2,000 CF
patients. In this study we investigated the effectiveness of VX-809/
VX-770 therapy on restoring CFTR function in human bronchial
epithelial (HBE) cells from R117H/F508del CF patients. We found
that VX-809 stimulated more CFTR activity in R117H/F508del HBEs
than in F508del/F508del HBEs. R117H expressed exclusively in
immortalized HBEs exhibited a folding defect, was retained in the ER,
and degraded prematurely. VX-809 corrected the R117H folding
defect and restored channel function. Because R117 is involved in ion
conductance, VX-770 acted additively with VX-809 to restore CFTR
function in chronically treated R117H/F508del cells. Although treat-
ment of R117H patients with VX-770 has been approved, our studies
indicate that Orkambi may be more beneficial for rescue of CFTR
function in these patients.
cystic fibrosis; rare mutation; heterozygote; R117H; W1282X; VX-
809; VX-770; Orkambi
CYSTIC FIBROSIS (CF) IS CAUSED by mutations in the Cl channel
CFTR, a protein kinase A (PKA)-regulated anion channel (10,
30). CFTR functions in the apical membrane of various epi-
thelia and is responsible for Cl and HCO3 transport that is
vital for epithelial fluid and electrolyte homeostasis. Defective
CFTR channel function in CF airways impairs mucous hydra-
tion and the ability to expel inhaled pathogens effectively (15,
30). This leads to chronic airway infection, inflammation, and
lung fibrosis that is responsible for the majority of CF mor-
bidity and mortality.
CFTR is a large polytopic membrane protein that contains
two membrane spanning domains (MSD), two nucleotide bind-
ing domains (NBD), and a regulatory region (28). Assembly of
CFTR into an ATP-gated ion channel is dependent on proper
domain folding and interdomain assembly events that are
facilitated by sequential action of and cytosolic heat shock
protein (Hsp)70, Hsp40, and endoplasmic reticulum (ER) lu-
minal calnexin (3, 21, 29). There are more than 2,000 disease-
associated CFTR mutations that impact CFTR biogenesis and
function (32, 35), and the activity of protein quality machinery
influences the extent that mutant forms of CFTR are triaged
between biogenic and degradation pathways (22, 39, 40). The
most common mutation associated with CF is F508del, which
destabilizes NBD1 and thereby arrests channel assembly.
F508del CFTR is retained in the endoplasmic reticulum and
selected for premature degradation by the Hsp70-dependent E3
ubiquitin ligases RMA1/RNF5 and CHIP (16, 22, 39).
F508del CFTR accumulates in a nonaggregated and deter-
gent soluble state and can be brought back onto its folding
pathway with small molecule folding correctors (25, 40).
However, the assembly defect in F508del CFTR is severe and
monotherapy with currently available drugs that suppress mis-
folding of CFTR is of low efficacy (7, 33). The activity of
repaired F508del CFTR is also low because F508del causes a
defect in the ATP-dependent gating of the channel (35). There-
fore, use of a folding corrector (VX-809) in combination with
a channel potentiator (VX-770) is being employed to restore
CFTR function homozygous F508del CFTR patients. Around
70% of CF patients of European origin are homozygous for the
F508del CFTR mutation, the aforementioned drug combina-
tion termed Orkambi was recently approved to treat this patient
population (20).
Biochemical studies show VX-809 stabilizes MSD1 of
CFTR, thereby increasing the efficiency of F508del CFTR
folding (27). Action of VX-809 on MSD1 has broad benefits as
this leads to allosteric stabilization of CFTR folding interme-
diates and thereby overcomes folding defects caused by
F508del. Fortuitously, VX-809 action is not specific to F508del
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as it also acts on wild-type (WT) CFTR, and it restores proper
folding and function to some, but not all, rare CFTR mutants
(27, 34). Approximately 30% of the CF patient population has
a compound heterozygous CFTR mutant genotype comprised
of the F508del mutant in conjunction with a different, less
common mutated CFTR allele (10). The ability of folding
correctors to allosterically suppress folding inefficiencies in
CFTR suggests that pharmacotherapies developed to act on
F508del mutant can also be employed to restore proper hydra-
tion of epithelial cells in patients with rare CF-causing disease
alleles (2, 35).
R117H is a relatively common CF-causing mutation that is
associated with a moderate CF phenotype that has an early
clinical manifestation (24). Sweat chloride levels are markers
for CF and they range between 60 and 105 milliequivalents/l
(meq/l). F508del/F508 del patients have sweat chloride of
100 meq/l, whereas F508del/R117H 5T patients have sweat
chlorides of75 meq/l (32). The R117H allele is also found in
patients who have WT/R117H genotypes and do not have CF
but present in the clinic with congenital absence of the vas
deferens (14). The form of the R117H gene that is inherited by
CF patients has a shortened polythymidine tract (9T to 5T) that
causes variable skipping of exon 9 during processing of the
CFTR mRNA (6). Exon 9 encodes the first 60 amino acids of
NBD1, so its in-frame deletion results in the production of a
CFTR variant that cannot fold or function properly and is
rapidly degraded. In addition, the pools of R117H CFTR that
are translated from properly spliced mRNA exhibit a 25%
reduction in ion conductance and a 10-fold reduction in
channel opening probability (41). R117H CFTR is associated
with CF in 2,000 patients and since it has defective channel
function its activity might be restored through monotherapy
with the CFTR channel potentiator VX-770. However, resto-
ration of lung function was modest in R117H patients who
participated in a clinical trial with VX-770 (Kalydeco) (23).
To further understand factors that limit the ability of VX-770
to restore R117H CFTR function in lung airways we examined
the biogenesis of R117H CFTR in primary human bronchial
epithelia cells and in model epithelial cell lines. We report that
mutation of R117H causes a kinetic defect in the folding of
nascent R117H CFTR that leads to its accumulation in large
pools within the endoplasmic reticulum of polarized epithelial
cells. Remarkably, unlike F508del, the folding defect caused
by R117H is highly correctable. By itself the folding modulator
VX-809 is sufficient to restore significant levels of R117H
CFTR function at the cell surface. The activity of R117H
CFTR in VX-809-treated cells is further increased through
acute treatment with the potentiator VX-770. Additive in-
creases in activity of CFTR in R117H/F508del human bron-
chial epithelial (HBE) cells are also detected in response
chronic treatment with the combination of VX-809 and VX-
770. This is of relevance for treatment of CF patients carrying
the R117H mutation, because currently these patients have
access to VX-770 (Kalydeco) but not to VX-809 and VX-770
combination treatment (Orkambi).
METHODS
Culture of primary HBE cells. Human lung tissue was procured
under The University of North Carolina Office of Research Ethics
Biomedical Institutional Review Board Approved Protocol No. 03–
1396. Primary HBE cells were harvested and cultured using estab-
lished procedures previously described in detail (11, 13).
Production of UNCCF7T cell lines that express inducible WT and
mutant CFTR. UNCCF7T cells were created by lentiviral addition of
Bmi-1 and hTERT to primary HBE cells from a CFTR G542X
homozygous donor as previously described for non-CF and F508del
homozygous donors (12). These cells retain the ability to polarize and
differentiate as previously reported for the other genotypes. Due to the
double stop G542X mutation the fragment of CFTR synthesized is
degraded prematurely and the cells serve as a CFTR negative back-
drop for functional and biogenic studies on WT and mutant CFTR.
To express CFTR in UNCCF7T, the parental cells were expanded
to P7 and then seeded into treated Costar polystyrene plate (Corning,
Corning, NY). Cells were grown for 3 days in bronchial epithelial
growth medium (BEGM) to 40% confluence. Cells were washed
with PBS and then lentivirus that was packaged with pTRIPZ-CFTR
or pTRIPZ-R117H-CFTR was added to 1 ml of conditioned media
that contained 4 g of polybrene (Sigma-Aldrich, St. Louis, MO) and
the mixture was added directly to cells. Cells were incubated in viral
solution for 6 h before being washed twice with PBS and incubated in
BEGM for 48 h. Transduced cells containing the pTRIPZ vector were
selected with 1 g/ml puromycin (Sigma-Aldrich) and expanded on
polystyrene plates.
CFBE cell lines that express inducible form of WT and mutant
CFTR. The immortalized CF bronchial epithelial CFBE41o- (pro-
vided by J.P. Clancy, Univ. of Cincinnati) was seeded at a density of
20% onto treated Costar polystyrene plates (Corning, Corning, NY).
Cells were grown for 2 days in DMEM media (Life Technologies,
Carlsbad, CA) and washed with PBS. Then, 500 l of lentivirus that
harbors pTRIPZ-CFTR, pTRIPZ-F508del-CFTR, or pTRIPZ-R117H-
CFTR were mixed with 1 ml of conditioned of DMEM was added to
cells. Cells were incubated the virus enriched media for 6 h before
being washed with PBS and then incubated in DMEM for 48 h.
Transduced cells containing the pTRIPZ vector were selected with 1
g/ml puromycin and expanded on polystyrene plates.
Air liquid interface culture of stably transduced CFBE and
UNCCF7T cell lines. Cells were removed from polystyrene plates
with trypsin and reseeded into the apical compartment of 0.4-m pore
size Snapwell (Corning Costar, Cambridge, MA) or Millicell inserts
(Millipore, Bedford, MA) coated with placental type IV collagen
(Sigma-Aldrich) at a density of 0.2  106 cells/insert. Cells were
grown with air liquid interface (ALI) media in the basolateral and
apical compartment for 7 days, until confluent. Cells were then
maintained at an ALI. Three times per week, the apical surface was
washed with PBS and medium was replaced only in the basal
compartment. Cells were grown at ALI for 2–3 wk. Before exper-
imentation, cells were grown in ALI media containing 3 g/ml
doxycycline (Sigma-Aldrich) for 48 h to induce expression of CFTR.
Cells were then incubated in the presence or absence of 5 M VX-809
(Selleckchem, Houston, TX) and doxycycline for an additional 48 h.
Western blot analysis of endogenous CFTR expression in polarized
HBEs. Indicated HBE cultures that were treated as described in the
figure legends and were dissolved in NP-40 lysis buffer containing
protease inhibitors. CFTR was immunoprecipitated from cleared ly-
sates with rabbit anti-CFTR polyclonal antibody 155 and protein A/G
PLUS-agarose beads (Santa Cruz Biotechnology). Immune precipi-
tated material was eluted from the agarose beads and separated by
SDS-PAGE and CFTR was detected by Western blot with primary
CFTR antibodies (596, 217) or actin and then fluorophore-conjugated
secondary antibodies. Proteins were visualized using a LI-COR Od-
yssey scanner.
Measurement of CFTR activity in Ussing chambers. Ion transport
measurements with HBEs were performed in modified Ussing cham-
bers (Physiologic Instruments) under voltage clamp-conditions using
Acquire & Analyze (version 2.3) software (Physiologic Instruments).
Reference measurements [potential difference (Pd)] and transepithe-
lial resistance (Rt) were obtained for each culture. Short circuit current
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(Isc) was measured every 20 s and recorded digitally after bilateral
equilibration at pH 7.4 for 10 min in 5 ml of pH 7.4 Krebs bicarbonate
Ringers (KBR; 115 NaCl mM, 25 NaHCO3 mM, 2.4 K2HPO4 mM,
1.2 CaCl2 mM, 1.2 MgCl2 mM, 0.4 KH2PO4 mM, and 5 D-glucose
mM). Chamber temperature was maintained at 36°C  1°C by a
circulating water bath and KBR was bubbled with 95% O2-5% CO2
throughout the experiment.
For measurements of CFTR currents in polarized CFBE cells, the
cultures were equilibrated in bilateral KBR for a minimum of 5 min,
and Isc was measured in a 5- to 120-mM Cl gradient. The gradient
was generated by replacing the apical buffer with a high-potassium,
low-chloride buffer (HKLC, pH 7.4) that contained the following: 15
mM gluconate, 95 mM gluconate, 25 mM NaHCO3, 2.4 mM
K2HPO4, 1.2 mM CaCl2, 1.2 mM MgCl2, and 0.4 mM KH2PO4.
Agonists and inhibitors used to modulate CFTR activity were
purchased from Sigma Chemical. In the presence of amiloride (100
M, apical), forskolin (10 M) was applied bilaterally to induce
cAMP activation of CFTR, and VX-770 (5 M, apical) was applied
to further activate CFTR. Currents detected were sensitive to the
CFTR channel blocker CFTRinh-172 (10 M apical). As an internal
control, UTP (100 M) was used to activate calcium activated
chloride channels (CaCC) at the conclusion of the experiment. Data
were exported and analyzed in Microsoft Excel, and slope values were
subtracted for accuracy when necessary. Mean, SD, and SE measure-
ments were calculated for each culture. Statistical analysis was per-
formed by an unpaired two-tailed Student’s t-test. P  0.05 was
considered to indicate statistical significance. Line and Bar graphs
were created using Origin 8.6 Software (OriginLab).
Microscopic analysis of R117H localization in UNCCF7T cells.
UNCCF7T cells grown on millicell inserts were frozen in Tissue-Tek
optimal cutting temperature compound (Sakura Finetek, Torrance,
CA), and frozen sections were prepared as previously described (4).
Fixation of cells for microscopy was performed using a method
similar to that previously described (1). Frozen sections placed into
20°C acetone and incubated at room temperature for 5 min. Slides
were then removed from acetone and dried at room temperature.
Slides were placed in a humidified chamber and covered with 100 l
of the cross-linker bis[sulfosuccinimidyl] suberate (BS3; 100 M) for
30 min. BS3 solution was washed from the coverslips and replaced
with 100 l of 1 M glycine for 15 min. Glycine was then removed,
Slides were washed three times with PBS, and 100 l of blocking
buffer (PBS with 1% FBS, 1% milk) was put onto the coverslips for
1 h. Slides were incubated with primary antibody diluted in blocking
buffer for 1 h. CFTR was immunostained with the mouse monoclonal
antibodies 596 and 660 (9). Rabbit anti-Calnexin was obtained from
Sigma-Aldrich. Slides were then incubated with Texas Red and Alexa
Fluor 350-conjugated secondary antibodies (Life Technologies) di-
luted in blocking buffer with DAPI stain for 1 h. Slides were washed
three times with PBS and mounted onto slides using mounting media.
Samples were imaged with a IX81 motorized inverted microscope
(Olympus, Center Valley, PA). Images were acquired using Meta-
Morph (Molecular Devices, Sunnyville, CA).
Chronic CFTR rescue with VX-809 and VX-770. CF HBE cultures
were maintained at ALI on 12-mm Millicell Cell Culture Inserts
(Merck Millipore) for 20–28 days and then treated with 0.1% DMSO
(vehicle) or 3 or 5 M VX-809, 5 M VX-770, or both compounds
in 0.1% DMSO. Vehicle and/or compounds were added to ALI media
and then exposed to cultures basolaterally (2 ml) and apically (20 l)
for 48 h before Ussing chamber measurements, with a fresh media
plus vehicle or compound exchange after 24 h.
RESULTS
To test the concept that compound heterozygous CF patients
can be treated with drugs developed to restore function of
F508del CFTR, the action of VX-809 on function and folding
of CFTR in patient cells with R117H/F508del mutations was
explored. To calibrate the experimental system we compare
results obtained with R117H/F508del to those obtained with
HBE cells that harbor W1282X/F508del, F508del/F508del,
and E60X/F508del. W1282X is a relatively common CFTR
mutation allele that encodes a truncated mRNA that is subject
to non-sense mediated decay and the protein product from
W1282X mRNA cannot fold and is degraded prematurely (18,
35). E60X is a rare allele that produces a truncated mRNA and
almost no CFTR protein product, so studies with W1282X/
F508del and E60X/F508del enable us to estimate the contri-
bution of the single copy of F508del to total CFTR activity
R117H/F508del heterozygous HBEs.
HBEs are grown on semipermeable supports to promote
polarized growth and then shifted to an ALI to drive differen-
tiation of primary epithelial cells to a state that closely resem-
bles that of lung airway epithelium (11). Fully differentiated
HBEs were treated with 3 M VX-809 for 48 h. and levels of
folded CFTR, termed the C-form, and the nonnative and
ER-localized pool, termed the B-form, of CFTR were mea-
sured by Western blot (Fig. 1A). Under control conditions, the
B-form of CFTR was detected in all cells regardless of geno-
type. The C-form of CFTR was detected in R117H/F508del
and was increased around 2-fold by VX-809. The levels of the
C-form in E60X/F508del CFTR and W1282X/F508del were
also increased to a lesser extent by VX-809. The twofold
increase in the signal for folded CFTR in VX-809 treated
R117H/F508del and the more modest increase in the C-form
detected in E60X/F508del CFTR and W1282X/F508del HBEs
suggest that biogenesis of R117H CFTR can be positively
impacted by folding correctors.
Measurements of transepithelial short-circuit currents in
Ussing chambers indicated that CFTR Cl- channel activity in
R117H/F508del HBE cells was also increased above that
detected in F508del/F508del HBE cells following 48 hrs.
chronic treatment with 3 M VX-809 (Fig. 1, B and D).
Forskolin- mediated cAMP activation of CFTR-mediated cur-
rents reached 7 A/cm2 in R117H/F508del whereas currents in
W1282X/F508del, E60X/F508del, and F508del/F508del (Fig.
1, B and F–G) were below 1 A/cm2. When we measured the
forskolin-stimulated CFTR currents in Ussing chambers in
quadruplicate for normal HBE cells that were derived from
eight different individuals (n 	 32) and grown under these
same growth conditions, CFTR currents were on average 33 
2 A/cm2 (SE). Uncorrected CFTR activity in R117H/
F508del is therefore 20% of normal, but is increased to 33%
of normal (11 A/cm2) by VX-809 (Fig. 1, B and D). Addition
of the channel potentiator VX-770 increased CFTR activity in
R117H/F508del an additional 30%. These results demonstrate
that the combined use of VX-809 and VX-770 can effectively
restore CFTR activity in HBEs from heterozygous R117H/
F508del CF patients.
R117H causes a folding defect in CFTR that is suppressed
by VX-809. To evaluate the impact of R117H on CFTR
biogenesis, independent of F508del, studies were conducted in
transiently transfected HEK293 cells (Fig. 2, A–D). Based on
molecular modeling, of the CFTR structure (31), R117 is
predicted to be located at the tip of TM1 and be exposed in the
ER lumen during biosynthesis of CFTR (Fig. 2A). With the use
of the program Eris (38) to estimate changes in CFTR stability
caused by R117H, R117H is predicted to change the delta-
delta-G of CFTR by 
1 kcal/mol. R117H does not dramati-
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cally destabilize the final structure of properly folded CFTR
but has the potential to cause subpopulations of CFTR folding
intermediates to go off pathway. Indeed, R117H causes a
defect in folding of newly synthesized CFTR: the C-form of
R117H CFTR accumulates at 70% lower levels than the
C-form of CFTR (Fig. 2B, lane 1 vs. 2). Accumulation of
folded R117H CFTR was stimulated to different extents by
addition of different folding correctors to the cell culture media
(Fig. 2B). C18 and VX-809 are structurally related and were
the most efficacious, driving accumulation of folded R117H
CFTR to between 100 and 200% of WT CFTR levels (lane 2
vs. 7 and 8). C17 is a corrector that is structurally related to
Corr4a and acts on MSD2 to suppress folding defects in CFTR
(17). Addition of C17 to cell culture media restored R117H
CFTR folding to 60% of WT levels (lane 2 vs. 6). R117H
exhibits a biogenic defect that is effectively suppressed by
action of VX-809 on MSD1. The lack of cooperation between
VX-809 and C17 on R117H CFTR indicated that modulation
of the conformation of MSD1 by VX-809 is sufficient to
overcome folding defects caused by the R117H mutation.
To assess the impact of R117H on the kinetics of CFTR
folding we took advantage of the fact that the efficiency of
CFTR folding is limited by the basal activity of the cytosolic
and ER associated molecular chaperones that scan the ER
membrane for proteins that contain non-native protein structure
and selected them for proteasomal degradation (16, 39). Re-
ductions in ERQC activity increase efficiency of CFTR fold-
ing, and increasing activity has reciprocal effects. Interestingly,
inhibition of the proteasome with bortezomib resulted in a
threefold increase in the accumulation of the ER-localized
B-form of R117H CFTR (Fig. 2C), but a corresponding
increase in the folded C-form was not detected. While the
presence of bortezomib increases the pool of the B-form of
CFTR, there was no dramatic increase in the efficacy of C18
and VX-809 at accumulation of the folded R117H CFTR
(Fig. 2C).
In pulse-chase studies, the conversion of the B-form of
R117H CFTR to the folded C-form occurred at low efficiency
(Fig. 2D). VX-809 was able to suppress kinetic defects in
R117H CFTR biogenesis because the drug increased the pool
of the newly synthesized B-form and promoted its relatively
efficient conversion to the C-form of R117H CFTR (Fig. 2D,
compare lane 1 of respective bottom left and right). Thus
R117H causes a kinetic defect in CFTR folding that is sup-
pressed by folding modulators. These data help explain why
VX-809 strongly stimulates accumulation of the C-form of
CFTR in R117H 5T/F508del HBE cells (Fig. 1A).
Fig. 1. Biochemical and functional response of cystic fibrosis transmembrane conductance regulator (CFTR) to corrector (VX-809) and potentiator (VX-770) in
primary human bronchial cells (HBE) with heterozygous cystic fibrosis disease alleles. A: impact of VX-809 on accumulation of CFTR in HBE cells with the
genotypes R117H CFTR 5T/F508del, W1282X/F508del, and E60X/F508del. HBE cultures were chronically treated for 48 h with 3 M VX-809 or 0.1% DMSO
(vehicle). Treatment with VX-809 resulted in an increase in CFTR protein levels. Bar graphs represent the mean net response (n 	 4 cultures per genotype) to
acutely added forskolin (B) and CFTRinh172 (C) in Ussing chamber experiments. Representative traces (D–G) illustrate the response of each heterozygous
mutation to the stimulation protocol. *Values that are significantly different than control, P  0.05 by Student’s t-test.
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VX-809 suppresses intracellular accumulation of R117H
CFTR. The aforementioned pulse-chase studies suggest that a
population of newly synthesized R117H CFTR goes of path-
way and is degraded before it can fold. Therefore, the extent
that R117H leads CFTR to be retained within intracellular
membranes of polarized human lung epithelial cells was eval-
uated (Fig. 3). To conduct these experiments, we employed
593X CFTR UNCCF7T cells that are generated from human
bronchial epithelial cells (12). 593X CFTR UNCCF7T cells
are devoid of CFTR because they are homozygous for 593X
CFTR, but the truncated 593X mRNA is CFTR degraded by
nonsense mediated decay; hence no CFTR signal is detected by
fluorescence microscopy in these cells (Fig. 3, row 1, left).
593X CFTR UNCCF7T cells are therefore functionally null
hosts for CFTR and permit study of WT CFTR and R117H
CFTR biogenesis in native-like differentiated epithelial cells.
When we expressed CFTR in UNCCF7T, we saw successful
trafficking of it to the cell surface (Fig. 3, row 2). In contrast,
large intracellular pools of R117H CFTR were detected in
locations that overlap with calnexin, and detection of R117H
CFTR on the cell surface was difficult (Fig. 3, row 3). Calnexin
staining is used a marker for the ER membrane, and the ER of
polarized UNCCF7T is present throughout the cell, so calnexin
staining is wide spread. Notably, the presence of VX-809,
caused a shift in localization of R117H CFTR to the surface of
polarized UNCCF7T cells (Fig. 3, row 4). These data support
the conclusion that R117H CFTR has a highly correctable
trafficking defect that limits its cell surface accumulation in
polarized human epithelial cells.
R117H CFTR function in polarized bronchial epithelial cells
is restored by combination treatment with VX-809 and VX-770.
To assess the extent that functional defects reported for R117H
CFTR can be restored in polarized epithelial CFBE41o- cells
that only express this CFTR variant, we measured cAMP-
dependent CFTR channel activity in Ussing chambers (Fig. 4,
A–I). Forskolin acts to increase intracellular level of cAMP and
stimulated currents in cells that express R117H CFTR to
around 30 A/cm2 (Fig. 4, A and B) vs. 5 for F508del (Fig. 4,
D–F) and 100 for WT CFTR (Fig. 4, G–I). Treatment of cells
with VX-809 for 24 h before assay lead to a large increase in
accumulation of the C-form of R117H (Fig. 4C), and more
modest increases in F508del (Fig. 4F) and WT (Fig. 4I).
Increases in levels of R117H CFTR correlated with VX-809-
dependent increases in its channel activity to around 100
A/cm2 (Fig. 4A). R117H CFTR currents were further in-
creased by the channel potentiator VX-770 and were oblated
by the CFTR inhibitor CFTRinh172 (Fig. 4B), so R117H CFTR
activity can be restored by VX-809 and VX-770 to level that
surpass that of F508del CFTR. R117H CFTR has both folding
and functional defects that are strongly suppressed by modu-
lator and potentiator therapy in polarized CFBE cells.
Maximum CFTR function in R117H/F508 HBE cells is
achieved with chronic treatment using the combination of
VX-809 and VX-770. Acute addition of VX-770 to HBEs
treated with VX-809 for over 24 h maximally stimulates CFTR
in F508del/F508del cells. Yet, long-term exposure of HBEs
with VX-770 is reported to reduce F508del CFTR folding
efficiency and decrease its stability at the cell surface (5, 36).
Therefore, the efficacy of chronic treatment with of R117H
5T/F508del HBEs with VX-809 and VX-770 was examined
(Fig. 5). Interestingly, CFTR activity in R117H 5T/F508
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Fig. 2. R117H CFTR exhibits a folding defect that is corrected by VX-809. A:
model for CFTR structure showing the location of R117 and F508. B: the
impact of folding modulators on the accumulation of the folded C-form and ER
localized B-form of CFTR in HEK293 cells. C: the impact that inhibition of the
ERAD pathway with Bortezomib has on the ability of folding modulator to
promote accumulation of the folded C-form of R117H CFTR. D: analysis of
kinetic defects in R117H CFTR folding as determined by pulse-chase analysis.
HEK293 cells were transfected with the indicated form of CFTR and incubated
with the indicated folding modulator at a concentration of 5 M. Cells were
lysed and levels of CFTR were measured by western blot 18 h after addition
of the specified folding modulator. For pulse-chase studies HEK293 cells were
transfected with CFTR or R117H CFTR and treated with DMSO or 5 M
VX-809 for 1 h before the 20-min labeling period with 35S-translabel. CFTR
was immuneprecipitated from cells extracts after the indicated incubation time
and 35S-CFTR was detected by SDS-PAGE and autoradiography.
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HBE cells was maximal when cells were treated chronically
with 5 M VX-809 and 1 M VX-770 (Fig. 5, A and B). In
addition, activity of CFTR in R117H 5T/F508 HBEs was
stable on the presence of VX-770 (Fig. 5, A and B), and this is
in contrast to the activity of CFTR in F508del/F508del (5, 36).
These data suggest that the R117H CFTR channel is stabile in
the presence of VX-770 and VX-809, and combination therapy
with these drugs could benefit patients with the R117H 5T/
F508 CFTR genotype.
DISCUSSION
Treatment of the entire population of CF patients requires
the development of personalized therapeutic approaches be-
cause individuals inherit different combinations of disease
alleles and disease phenotypes do not always correlate with a
patient’s genotype (8, 10, 32, 35, 37). Combination therapy
with the folding corrector VX-809 and channel potentiator
VX-770 for treatment of homozygous F508del/F508del pa-
tients was recently approved by the FDA. This advance
spawned interest in the treatment of compound heterozygous
CF patients with both VX-809 and VX-770. Yet, individual
disease alleles cause different defects in biogenesis and func-
tion of CFTR, so study of the efficacy of VX-809/VX-770 at
restoring function of CFTR in heterozygous CF patients re-
quires a case-by-case analysis. Two of the most common
heterozygous CF genotypes, collectively representing 4% of
the CF population, are R117H CFTR 5T/F508del, and
W1282X/F508del. Our studies show that W1282X/F508del
HBEs respond poorly to VX-809 and VX-770, yet chronic
treatment of R117H/F508del HBEs serves to restore CFTR
folding and function to levels that were significantly above
those detected in F508del/F508del cells. The FDA-approved
VX-770 for CF patients with R117H mutation (23), and data
presented in this study and by other groups suggest that
restoration of R117H expression and folding will further in-
crease R117H CFTR function as follows: 1) R117H CFTR 5T
mRNA is not processed efficiently, so level levels of the
channel that are translated from properly processed transcripts
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Fig. 3. VX-809 suppresses the intracellular accumu-
lation of R117H CFTR in polarized bronchial epithe-
lial cells. Fluorescence micrographs of frozen sections
of UNCCF7T cells expressing wild-type (WT) or
R117H CFTR were treated with VX-809 (5 M) for
48 h. CFTR (green) and Calnexin (red) were immu-
nostained. Nuclei were stained with DAPI (blue).
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are low (19). 2) We report that nascent R117H CFTR has a
folding defect that further limits its cell surface expression and
activity. 3) R117H CFTR has a gating defect that prevents
properly folded R117H CFTR functioning as an ion channel to
regulate the hydration of airways (41). VX-809 is able to
restore folding of R117H CFTR toward normal and VX-770
can overcome gating defect caused by R117H. Yet, neither
drug appears capable of suppressing defects in R117H 5T
Fig. 4. R117H CFTR activity in polarized CFBE cells is increased several-fold by VX-809 and VX-770. CFBE41o- cells expressing R117H (A–C), F508del
(D–F), or WT CFTR (G–I) grown at air liquid interface (ALI) were pretreated with doxycycline for 4 days and then treated with 0.1% DMSO (vehicle) or 5
M VX-809 for 48 h. Short circuit current (Isc) measurements of CFBE41o- cultures were recorded in Ussing chambers using agonists and inhibitors as described
in METHODS. Representative Isc traces of CFBEs expressing (A) R117H, (D) F508del, or (G) WT CFTR are shown. Mean responses (n	 3 cultures per genotype)
are represented as bar graphs (B, E, and H). Treatment with VX-809 resulted in increased CFTR function. To visualize the amounts of CFTR protein present
in treated cells, Western blot analyses were conducted in CFBE41o- cells expressing R117H (C), F508del (F), or WT CFTR (I). After treatment with vehicle
or VX-809, cells were lysed and then proteins were analyzed by Western blot using antibodies against CFTR or actin. Treatment with VX-809 led to an increase
in mature CFTR protein levels. *Values that are significantly different than control, P  0.05 by Student’s t-test.
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CFTR mRNA processing. However, combination treatment
with VX-809 and VX-770 additively restores CFTR function
in R117H 5T/F508del cells to 12.5 A/cm2, which is40% of
WT CFTR function. R117H is associated with mild forms of
CF, so there is potential for VX-809 and VX-770 to restore
CFTR function in R117H 5T CF patients to clinically signifi-
cant levels.
F508del CFTR is an unstable protein that has a short
half-life in the ER and cell surface and these issues contribute
to the low efficacy observed for VX-808/VX-770 combination
therapy for F508del/F508del patients. An additional issue is
suggested by observations that chronic treatment of F508del/
F508del HBE cultures with VX-770 decreases the quantity of
corrected F508del CFTR channels that accumulate when cells
are treated with VX-809 alone (5, 36). This appears to occur
because VX-770 destabilizes F508del CFTR and induces its
turnover. Interestingly, R117H CFTR does not appear to be
destabilized by VX-770 as chronic treatment of R117H/
F508del HBEs with both VX-770 and VX-809 results in an
additive increase in total CFTR activity. Since chronic combi-
nation treatment of R117H cells with VX-809 and VX-770
leads to even higher CFTR-mediated responses, VX-770 does
not severely abrogate VX-809-mediated correction of R117H.
These data illustrate the need to study the impact of potentiator
and folding corrector therapies on mutant forms of CFTR on a
case-by-case basis.
Insights into the mechanism for misfolding of nascent CFTR
caused by the R117H mutation come from structural modeling
of the folded channel (Fig. 2A; see METHODs for details). R117
is predicted to be located on the termini of the helix that
extends from TM1 into the ER lumen and connects to TM2
through extracellular loop 1. TM1 and TM2 form a bundle of
helices that assemble with TM9-12 to become one wing of the
CFTR channel, whereas TM3-6 assemble with TM7-8 to form
the second wing. H117 is predicted to be oriented differently
than R117 and is rotated toward TM10 and this has the
potential to decrease the efficiency by which TM1/TM2 are
assembled into a complex with TM9-12. The RMA1/RNF5 E3
and Hsp70/CHIP ubiquitin ligase complexes sense defects in
the assembly of membrane domains of CFTR (16, 26, 39), so
even subtle defects in the assembly of CFTRs TM segments
caused by R117H will be detected by ERQC. VX-809 acts on
MSD1 to suppress folding defects in CFTR caused by F508del
and is thereby able to increase the efficiency of CFTR mem-
brane domain assembly (27). Therefore, the ability of VX-809
to restore R117H CFTR folding to WT levels is consistent with
the drug stabilizing MSD1 to increase the efficiency of intra-
domain protein assembly interactions to overcome folding
defects imparted by R117H.
During the CF communities, initial characterization of
CFTR mutation alleles, defects exhibited were grouped into
distinct classes that included class I, defective expression;
class II, defective folding/trafficking; class III, defective
gating: class IV, defective conductance; class V, defective
mRNA splicing; and class VI, defective cell surface stabil-
ity. It is now becoming clear that the same mutation in the
CFTR coding sequence and/or intron can cause more than
one type of biogenetical and/or functional defect (35).
R117H 5T is a complex disease allele is considered a class
I, II, IV, and V mutant, whereas, F508del CFTR is a class II,
III, VI mutant. The realization that mutations in CFTR can
cause a broad spectrum of abnormalities will help design
future therapies with different combinations of drugs that
target specific defects in CFTR biology. There are over
2,000 disease-related CFTR alleles and many are inherited
heterozygously. The studies presented provide and outline
on how to study functional correction of mixed CFTR
alleles in native and model cells. Future studies will be
focused on expanding investigations of molecular mecha-
nisms and pharmacological rescue to other CFTR rare al-
leles with the goal being to provide in vitro data that will
guide the development of personalized approaches to treat
CF patients with different genotypes.
Fig. 5. Chronic treatment with VX-809 and VX-770 additively increases CFTR function in R117H CFTR 5T/F508del HBE cells. A: representative Isc traces of
HBE cells (R117H/F508del) recorded in Ussing chambers. Cultures were treated with vehicle (0.1% DMSO), 5 M VX-809, 1 M VX-770, or 5 M VX-809
plus 1 M VX-770 for 48 h. B: CF HBE cells chronically treated with VX-809 combined with VX-770 showed a significant increase in responses to forskolin
compared with VX-809 or VX-770 alone. Primary CF HBE cultures were derived from 3 different individuals (R117H/F508del, 5T/9T), and 3–4 replicates were
performed per individual for a total of 10 measurements per condition. *Values that are significantly different than control, P  0.05 by Student’s t-test.
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